EUVIMEDOpdag EUVIMED
Crossref

Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis

Arpan Mohanty iD, Yin Wang iD, Charles Stoecker

Obesity · 2025-10 · 33 (10) · 1845-1848

DOI: 10.1002/oby.70005 ↗

At a glance

Journal article in Obesity, published online on 2025-08-13. Written by Arpan Mohanty and 2 co-authors. Institution: Section of Gastroenterology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, USA. Major MEDLINE topics: Obesity, Liver Cirrhosis, Mass Screening. Cited 3 times so far (Crossref); 17 references. Funded by: Gilead Sciences.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

The study aimed to compare the cost‐effectiveness of various strategies for screening for MASLD‐related advanced hepatic fibrosis (fibrosis stage > 2) using the fibrosis‐4 index (FIB‐4) and liver stiffness measurement (LSM) by transient elastography (TE) in persons with obesity.

Methods

We created a decision‐analytic model comparing three screening strategies: no screening, TE, and FIB‐4 followed by TE. We used a Markov transition model to track liver state, with prevalence and transition probabilities specific to the population with obesity. If MASLD was detected, patients were treated with resmetirom.

Results

We found an incremental cost‐effectiveness ratio (ICER) of $234,781 (95% CI: $232,581, $235,608) when comparing TE to no screening with a 10‐year interval. We note the ICER of $234,673 (95% CI: $234,033, $235,072) when comparing TE to FIB‐4+TE. In multivariate simulations, we found no screening was most likely to be cost‐effective for willingness‐to‐pay for QALY below approximately $250,000.

Conclusions

Our results suggest routine screening for MASLD in obesity clinics is not cost‐effective with resmetirom as the available treatment. A prescreening with FIB‐4 before TE did not increase economic efficiency.

Subjects

MeSH terms (MEDLINE)

ObesityLiver CirrhosisMass ScreeningHumansCost-Benefit AnalysisElasticity Imaging TechniquesMaleFemaleMiddle AgedMarkov ChainsAdultDecision Support TechniquesCost-Effectiveness Analysis

Author keywords

FIB‐4MASLDTEclinically significant liver fibrosisobesityscreening

Authors and institutions

  • Section of Gastroenterology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.
  • Department of Health Policy and Management, Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.

ORCID profiles: Arpan Mohanty, Yin Wang

Funding

  • Gilead Sciences

Cite

APA

Mohanty, A., Wang, Y., & Stoecker, C. (2025). Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis. Obesity, 33(10), 1845-1848. https://doi.org/10.1002/oby.70005

Vancouver

Mohanty A, Wang Y, Stoecker C. Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis. Obesity. 2025;33(10):1845-1848. doi:10.1002/oby.70005

BibTeX
@article{Mohanty2025,
  author = {Mohanty, Arpan and Wang, Yin and Stoecker, Charles},
  title = {Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis},
  journal = {Obesity},
  year = {2025},
  volume = {33},
  number = {10},
  pages = {1845--1848},
  doi = {10.1002/oby.70005}
}
Start for free →